vafidemstat + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Borderline Personality Disorder
Conditions
Borderline Personality Disorder
Trial Timeline
Mar 26, 2021 → Nov 13, 2023
NCT ID
NCT04932291About vafidemstat + Placebo
vafidemstat + Placebo is a phase 2 stage product being developed by Oryzon Genomics for Borderline Personality Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04932291. Target conditions include Borderline Personality Disorder.
What happened to similar drugs?
0 of 4 similar drugs in Borderline Personality Disorder were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04932291 | Phase 2 | Completed |
Competing Products
12 competing products in Borderline Personality Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olanzapine + placebo | Eli Lilly | Phase 3 | 40 |
| olanzapine | Eli Lilly | Pre-clinical | 26 |
| Olanzapine | Eli Lilly | Phase 3 | 40 |
| Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab + Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate | Jiangsu Hengrui Medicine | Phase 2 | 31 |
| Durvalumab + Tremelimumab + Gemcitabine + Cisplatin | AstraZeneca | Phase 2 | 27 |
| quetiapine extended-release + Placebo | AstraZeneca | Phase 3 | 40 |
| Quetiapine fumarate + Placebo | AstraZeneca | Phase 2 | 35 |
| Quetiapine Fumarate | AstraZeneca | Phase 3 | 40 |
| ziprasidone + Placebo | Pfizer | Phase 2 | 35 |
| Fluorouracil + Irinotecan + Irinotecan Hydrochloride + Leucovorin + Leucovorin Calcium + Nivolumab + Oxaliplatin | Bristol Myers Squibb | Phase 1 | 29 |
| PD-1/PD-L1 inhibitors + Chemotherapy | BeOne Medicines | Phase 2 | 36 |
| Fluorouracil + Irinotecan + Leucovorin + Leucovorin Calcium + Oxaliplatin + Quemliclustat + Zimberelimab | Arcus Biosciences | Phase 1/2 | 33 |